The Kennedy family this morning announced the passing of Sen. Edward Kennedy from brain cancer. The Cancer Therapy & Research Center (CTRC) at the UT Health Science Center at San Antonio — one of the three National Cancer Institute-designated Cancer Centers in Texas — is making available neuro-oncology experts to comment on the type of cancer Sen. Kennedy had, its typical prognosis and advances in its treatment.
They are Andrew Brenner, M.D., Ph.D.; John Floyd, M.D.; and Aidnag Diaz, M.D.
Please call Jill Byrd at the CTRC, 450-5550, or Will Sansom at the UT Health Science Center, 567-2579, to set up your interviews.
In addition, a “Brain Tumor Education Series,” a set of four weekly talks for patients and caregivers, starts Friday, Sept. 4, and continues through Sept. 25. The free talks are from noon to 1 p.m. at the CTRC library in the first floor of the Grossman Building, 7979 Wurzbach Road. To register for the series, call 450-5574. Lunch will be provided free.
The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the nation’s leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of the elite cancer centers in the country to be named a National Cancer Institute (NCI)-designated Cancer Center, and is one of only three in Texas. A world leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) is internationally recognized for conducting one of the largest oncology Phase I clinical drug programs in the world, and participates in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit www.ctrc.net.